Eli Lilly is acquiring three vaccine developers including Curevo Vaccine for a combined ~$20B as it pushes into infectious disease. The deal signals a strategic pivot beyond GLP-1 dominance, but near-term EPS dilution and insider selling create a nuanced setup rather than a clean breakout.
Eli Lilly is acquiring three vaccine developers including Curevo Vaccine for a combined ~$20B as it pushes into infectious disease.
Fade the LLY M&A pop near-term — $20B spending spree with insider selling and no disclosed price target suggests the street needs time to underwrite the new strategy.
A rapid sell-side consensus upgrade with higher price targets, strong Q2 earnings beat on GLP-1 volumes, or FDA fast-track on a vaccine asset would quickly reverse the short thesis and squeeze LLY higher through its prior highs.
CoverageSource: Google News · Published here WED, MAY 27 · 9:00 AM ET · the only report in this recordHow this is decided →
LLY is up ~1.7% on the day but is deploying ~$20B into an unproven vaccines franchise while insiders have been selling (0 buys, 2 sells in last 30 days). Consensus is a broad Buy but no updated price target is listed, suggesting analysts haven't yet re-rated the stock post-announcement. M&A-driven dilution events historically see the initial pop fade 2-4 weeks as sell-side models are revised to absorb deal drag on near-term EPS. The GLP-1 growth story that commands LLY's premium multiple is now being diluted by capital allocation into lower-margin infectious disease assets.
The read above, as written. kept as written
2-4 weeks. Follow to be told when one lands.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →